Taysha Gene Therapies (TSHA) Accumulated Depreciation (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Accumulated Depreciation data on file, last reported at $5.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Depreciation rose 30.28% year-over-year to $5.0 million; the trailing twelve-month figure through Mar 2026 stood at $5.0 million (up 30.28% YoY), and the FY2025 full-year result was $4.7 million, up 30.69% from the prior year.
• Accumulated Depreciation advanced to $5.0 million in Q1 2026, from $4.7 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $5.0 million in Q1 2026 to a low of $754000.0 in Q1 2022.
• A 5-year average of $3.0 million and a median of $3.3 million in 2024 frame the typical range for Accumulated Depreciation.
• Across the five-year window, Accumulated Depreciation jumped 1739.02% in 2022 and gained 12.03% in 2025, its largest moves.
• Tracing TSHA's Accumulated Depreciation over 5 years: stood at $1.6 million in 2022, then surged by 81.43% to $3.0 million in 2023, then gained by 20.31% to $3.6 million in 2024, then jumped by 30.69% to $4.7 million in 2025, then increased by 6.19% to $5.0 million in 2026.
• Business Quant data shows TSHA's Accumulated Depreciation at $5.0 million in Q1 2026, $4.7 million in Q4 2025, and $4.4 million in Q3 2025.